Sunday, April 05, 2020 4:02:06 AM
Japanese Women. Obstet. Gynecol. 96:521-8 (2000) (“Kurabayashi”) was published in
2000 and is prior art to the patents-in-suit.
Kurabayashi investigated the effects of administering purified EPA (96.5% EPA) at
a dose of 1.8 g/day in combination with estriol (the “EPA group”) as compared to estriol
therapy alone (the “control group”) for forty-eight weeks to hyperlipidemic, menopausal
women. (Ex. 1534 at 1.) Estriol is a form of estrogen that is commonly used in menopausal
women to alleviate the symptoms of menopause. (ECF No. 367 at 735:2-20.) As an
estrogen, estriol is known to elevate triglyceride levels. (Id.)
Despite coadministration with estriol, Kurabayashi reports a statistically significant
27% reduction in triglyceride levels in the EPA group. (Ex. 1534 at 3.) As compared to the control group, the EPA group experienced a statistically significant reduction in triglyceride
levels at the 12, 24, and 48-week checkpoints:
(Id. at 4.) Kurabayashi further reports that “[l]ow-density lipoprotein cholesterol levels in
both groups were significantly lower.” (Id. at 3.)
Kurabayashi further reports a statistically significant reduction in Apo B levels in the
EPA group of 6.9%. (Id. at 4-5.) With a p-value of < .001, EPA’s effects on Apo B were
highly significant. (Id.; see also ECF No. 367 at 737:1-23.) In contrast, Kurabayashi reports
a non-statistically significant 1.5% reduction in Apo B levels in the control group:
(Ex. 1534 at 5; see also ECF No. 367 at 737:1-23.)
The results reported in Kurabayashi do not suggest any interaction or synergy
between EPA and estriol. (ECF No. 367 at 735:21-736:9.) Instead, synergy is usually only
seen between drugs that have similar effects, such as two drugs that reduce blood
pressure. (Id.)
In light of the statistically-significant differential effects reported between the EPA
and control groups, a POSA would have attributed the reduction in Apo B to EPA. (Id. at
737:24-738:8.)
and
As explained above as to Defendants’ prima facie obviousness case, Mori found
that EPA did not raise LDL-C levels, and Kurabayashi suggested that EPA reduced Apo
B levels. (ECF No. 373 at 76-80, 246-47.) Further, while the Patent Office found that a
decrease in Apo B was an unexpected benefit constituting a valid secondary
consideration, the Patent Office’s examiner did not consider Kurabayashi. (Id. at 246-47.)
Where “the PTO did not have all material facts before it, its considered judgment may lose
significant force[.]” See i4i, 564 U.S. at 95. Thus, the Court finds that the unexpected
benefits secondary consideration does not weigh in favor of finding the Asserted Claims
nonobvious.
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM